Antibodies against trimeric S glycoprotein protect hamsters against SARS-CoV challenge despite their capacity to mediate FcgammaRII-dependent entry into B cells in vitro. (Q51803005)

From Wikidata

Jump to navigation Jump to search

scientific article published on 22 August 2006

Language	Label	Description	Also known as
English	Antibodies against trimeric S glycoprotein protect hamsters against SARS-CoV challenge despite their capacity to mediate FcgammaRII-dependent entry into B cells in vitro.	scientific article published on 22 August 2006

Statements

scholarly article

1 reference

Europe PubMed Central

12 April 2018

http://europepmc.org/abstract/MED/17049691

Antibodies against trimeric S glycoprotein protect hamsters against SARS-CoV challenge despite their capacity to mediate FcgammaRII-dependent entry into B cells in vitro. (English)

1 reference

Europe PubMed Central

12 April 2018

http://europepmc.org/abstract/MED/17049691

0 references

1 reference

based on heuristic

inferred from title

1 reference

based on heuristic

inferred from title

11

1 reference

Europe PubMed Central

12 April 2018

http://europepmc.org/abstract/MED/17049691

13

1 reference

Europe PubMed Central

12 April 2018

http://europepmc.org/abstract/MED/17049691

10

object named as

Sherif R Zaki

1 reference

Europe PubMed Central

12 April 2018

Anjeanette Roberts

3

object named as

Anjeanette Roberts

1 reference

Europe PubMed Central

12 April 2018

http://europepmc.org/abstract/MED/17049691

SIgN Immunomonitoring Platform

0 references

author name string

Yiu Wing Kam

1

1 reference

Europe PubMed Central

12 April 2018

http://europepmc.org/abstract/MED/17049691

François Kien

2

1 reference

Europe PubMed Central

12 April 2018

http://europepmc.org/abstract/MED/17049691

Yan Chung Cheung

4

1 reference

Europe PubMed Central

12 April 2018

http://europepmc.org/abstract/MED/17049691

Elaine W Lamirande

5

1 reference

Europe PubMed Central

12 April 2018

http://europepmc.org/abstract/MED/17049691

Leatrice Vogel

6

1 reference

Europe PubMed Central

12 April 2018

http://europepmc.org/abstract/MED/17049691

Shui Ling Chu

7

1 reference

Europe PubMed Central

12 April 2018

http://europepmc.org/abstract/MED/17049691

Jane Tse

8

1 reference

Europe PubMed Central

12 April 2018

http://europepmc.org/abstract/MED/17049691

Jeannette Guarner

9

1 reference

Europe PubMed Central

12 April 2018

http://europepmc.org/abstract/MED/17049691

Malik Peiris

12

1 reference

Europe PubMed Central

12 April 2018

http://europepmc.org/abstract/MED/17049691

Ralf Altmeyer

14

1 reference

Europe PubMed Central

12 April 2018

http://europepmc.org/abstract/MED/17049691

language of work or name

0 references

publication date

22 August 2006

1 reference

Europe PubMed Central

12 April 2018

http://europepmc.org/abstract/MED/17049691

1 reference

Europe PubMed Central

12 April 2018

http://europepmc.org/abstract/MED/17049691

25

1 reference

Europe PubMed Central

12 April 2018

http://europepmc.org/abstract/MED/17049691

729-740

1 reference

Europe PubMed Central

12 April 2018

http://europepmc.org/abstract/MED/17049691

4

1 reference

Europe PubMed Central

12 April 2018

http://europepmc.org/abstract/MED/17049691

Identification of a new human coronavirus

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2006.08.011

7 January 2021

Characterization and complete genome sequence of a novel coronavirus, coronavirus HKU1, from patients with pneumonia

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2006.08.011

7 January 2021

Severe acute respiratory syndrome

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2006.08.011

7 January 2021

The Coronavirus Spike Protein Is a Class I Virus Fusion Protein: Structural and Functional Characterization of the Fusion Core Complex

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2006.08.011

7 January 2021

Synthesis and characterization of a native, oligomeric form of recombinant severe acute respiratory syndrome coronavirus spike glycoprotein

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2006.08.011

7 January 2021

Angiotensin-converting enzyme 2 is a functional receptor for the SARS coronavirus

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2006.08.011

7 January 2021

Expression cloning of functional receptor used by SARS coronavirus

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2006.08.011

7 January 2021

CD209L (L-SIGN) is a receptor for severe acute respiratory syndrome coronavirus

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2006.08.011

7 January 2021

pH-dependent entry of severe acute respiratory syndrome coronavirus is mediated by the spike glycoprotein and enhanced by dendritic cell transfer through DC-SIGN

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2006.08.011

7 January 2021

Characterization of severe acute respiratory syndrome-associated coronavirus (SARS-CoV) spike glycoprotein-mediated viral entry

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2006.08.011

7 January 2021

S protein of severe acute respiratory syndrome-associated coronavirus mediates entry into hepatoma cell lines and is targeted by neutralizing antibodies in infected patients

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2006.08.011

7 January 2021

Neutralizing antibodies in patients with severe acute respiratory syndrome-associated coronavirus infection.

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2006.08.011

7 January 2021

Development and characterization of a severe acute respiratory syndrome-associated coronavirus-neutralizing human monoclonal antibody that provides effective immunoprophylaxis in mice

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2006.08.011

7 January 2021

Human monoclonal antibody as prophylaxis for SARS coronavirus infection in ferrets

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2006.08.011

7 January 2021

Prior infection and passive transfer of neutralizing antibody prevent replication of severe acute respiratory syndrome coronavirus in the respiratory tract of mice

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2006.08.011

7 January 2021

Severe acute respiratory syndrome coronavirus spike protein expressed by attenuated vaccinia virus protectively immunizes mice

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2006.08.011

7 January 2021

An efficient method to make human monoclonal antibodies from memory B cells: potent neutralization of SARS coronavirus.

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2006.08.011

7 January 2021

Evaluation of human monoclonal antibody 80R for immunoprophylaxis of severe acute respiratory syndrome by an animal study, epitope mapping, and analysis of spike variants

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2006.08.011

7 January 2021

A DNA vaccine induces SARS coronavirus neutralization and protective immunity in mice

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2006.08.011

7 January 2021

Neutralizing antibody and protective immunity to SARS coronavirus infection of mice induced by a soluble recombinant polypeptide containing an N-terminal segment of the spike glycoprotein

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2006.08.011

7 January 2021

A recombinant baculovirus-expressed S glycoprotein vaccine elicits high titers of SARS-associated coronavirus (SARS-CoV) neutralizing antibodies in mice

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2006.08.011

7 January 2021

Comparative evaluation of two severe acute respiratory syndrome (SARS) vaccine candidates in mice challenged with SARS coronavirus

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2006.08.011

7 January 2021

Immunogenicity and protective efficacy in monkeys of purified inactivated Vero-cell SARS vaccine

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2006.08.011

7 January 2021

Immunization with modified vaccinia virus Ankara-based recombinant vaccine against severe acute respiratory syndrome is associated with enhanced hepatitis in ferrets

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2006.08.011

7 January 2021

Evasion of antibody neutralization in emerging severe acute respiratory syndrome coronaviruses

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2006.08.011

7 January 2021

Virology: SARS virus infection of cats and ferrets

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2006.08.011

7 January 2021

Aetiology: Koch's postulates fulfilled for SARS virus

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2006.08.011

7 January 2021

Severe acute respiratory syndrome coronavirus infection of golden Syrian hamsters

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2006.08.011

7 January 2021

DC-SIGN and L-SIGN are high affinity binding receptors for hepatitis C virus glycoprotein E2

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2006.08.011

7 January 2021

Processing, stability, and receptor binding properties of oligomeric envelope glycoprotein from a primary HIV-1 isolate

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2006.08.011

7 January 2021

Differential maturation and subcellular localization of severe acute respiratory syndrome coronavirus surface proteins S, M and E.

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2006.08.011

7 January 2021

A mucosally targeted subunit vaccine candidate eliciting HIV-1 transcytosis-blocking Abs.

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2006.08.011

7 January 2021

Induction of mucosal and systemic immune responses by intranasal immunization using recombinant cholera toxin B subunit as an adjuvant.

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2006.08.011

7 January 2021

C-type lectins L-SIGN and DC-SIGN capture and transmit infectious hepatitis C virus pseudotype particles

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2006.08.011

7 January 2021

Severe acute respiratory syndrome associated coronavirus is detected in intestinal tissues of fatal cases.

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2006.08.011

7 January 2021

Comparison of the immunological and protective responses elicited by microencapsulated formulations of the F1 antigen from Yersinia pestis

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2006.08.011

7 January 2021

Expression of immunogenic glycoprotein S polypeptides from transmissible gastroenteritis coronavirus in transgenic plants

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2006.08.011

7 January 2021

Receptor-binding domain of SARS-CoV spike protein induces highly potent neutralizing antibodies: implication for developing subunit vaccine

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2006.08.011

7 January 2021

Cooperation between transmissible gastroenteritis coronavirus (TGEV) structural proteins in the in vitro induction of virus-specific antibodies

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2006.08.011

7 January 2021

Assembly of coronavirus spike protein into trimers and its role in epitope expression

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2006.08.011

7 January 2021

Adjuvants for human vaccines--current status, problems and future prospects

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2006.08.011

7 January 2021

Vaccines for mucosal immunity to combat emerging infectious diseases

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2006.08.011

7 January 2021

Mucosal immunization with surface-displayed severe acute respiratory syndrome coronavirus spike protein on Lactobacillus casei induces neutralizing antibodies in mice

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2006.08.011

7 January 2021

Role of IgA versus IgG in the control of influenza viral infection in the murine respiratory tract.

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2006.08.011

7 January 2021

Receptor-binding domain of severe acute respiratory syndrome coronavirus spike protein contains multiple conformation-dependent epitopes that induce highly potent neutralizing antibodies

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2006.08.011

7 January 2021

Identification of a critical neutralization determinant of severe acute respiratory syndrome (SARS)-associated coronavirus: importance for designing SARS vaccines

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2006.08.011

7 January 2021

Potent neutralization of severe acute respiratory syndrome (SARS) coronavirus by a human mAb to S1 protein that blocks receptor association

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2006.08.011

7 January 2021

Identification of an antigenic determinant on the S2 domain of the severe acute respiratory syndrome coronavirus spike glycoprotein capable of inducing neutralizing antibodies

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2006.08.011

7 January 2021

Neutralization and antibody-dependent enhancement of dengue viruses

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2006.08.011

7 January 2021

Studies on the pathogenesis of dengue infection in monkeys. II. Clinical laboratory responses to heterologous infection

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2006.08.011

7 January 2021

Enhancing antibodies in HIV infection

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2006.08.011

7 January 2021

Infectivity-enhancing antibodies to Ebola virus glycoprotein

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2006.08.011

7 January 2021

Antibody-dependent enhancement of viral infection: molecular mechanisms and in vivo implications

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2006.08.011

7 January 2021

Influence of FcgammaRIIA and MBL polymorphisms on severe acute respiratory syndrome.

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2006.08.011

7 January 2021

Inhibitors of cathepsin L prevent severe acute respiratory syndrome coronavirus entry

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2006.08.011

7 January 2021

Protease-mediated enhancement of severe acute respiratory syndrome coronavirus infection

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2006.08.011

7 January 2021

Severe acute respiratory syndrome coronavirus (SARS-CoV) infection inhibition using spike protein heptad repeat-derived peptides.

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2006.08.011

7 January 2021

Identification of antigenic sites mediating antibody-dependent enhancement of feline infectious peritonitis virus infectivity

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2006.08.011

7 January 2021

Structural bases of Fc gamma R functions.

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2006.08.011

7 January 2021

Multiple organ infection and the pathogenesis of SARS.

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2006.08.011

7 January 2021

SARS vaccine protective in mice

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2006.08.011

7 January 2021

Monoclonal antibodies to the spike protein of feline infectious peritonitis virus mediate antibody-dependent enhancement of infection of feline macrophages

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2006.08.011

7 January 2021

based on heuristic

inferred from DOI database lookup

Localization of antigenic sites of the S glycoprotein of feline infectious peritonitis virus involved in neutralization and antibody-dependent enhancement.

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2006.08.011

7 January 2021

based on heuristic

inferred from DOI database lookup

Early death after feline infectious peritonitis virus challenge due to recombinant vaccinia virus immunization

1 reference

https://pubmed.ncbi.nlm.nih.gov/17049691

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Identifiers

10.1016/J.VACCINE.2006.08.011

1 reference

Europe PubMed Central

12 April 2018

http://europepmc.org/abstract/MED/17049691

1 reference

Europe PubMed Central

12 April 2018

http://europepmc.org/abstract/MED/17049691

ResearchGate publication ID

0 references

Sitelinks

Wikipedia(0 entries)

Wikibooks(0 entries)

Wikinews(0 entries)

Wikiquote(0 entries)

Wikisource(0 entries)

Wikiversity(0 entries)

Wikivoyage(0 entries)

Wiktionary(0 entries)

Multilingual sites(0 entries)

Retrieved from "https://www.wikidata.org/w/index.php?title=Q51803005&oldid=1398160150"